Getinge (OTCMKTS:GNGBY – Get Free Report) shares reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $25.98 and last traded at $25.98, with a volume of 105 shares changing hands. The stock had previously closed at $25.80.
Wall Street Analysts Forecast Growth
Separately, Zacks Research upgraded Getinge from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Strong Buy”.
Read Our Latest Stock Report on Getinge
Getinge Price Performance
Getinge (OTCMKTS:GNGBY – Get Free Report) last posted its earnings results on Friday, July 17th. The company reported $0.38 earnings per share (EPS) for the quarter. Getinge had a return on equity of 11.12% and a net margin of 7.81%.The firm had revenue of $894.87 million for the quarter. Equities analysts anticipate that Getinge will post 1.38 earnings per share for the current year.
About Getinge
Getinge AB is a global medical technology company that develops, manufactures and markets products and systems for hospitals and life sciences institutions. The company’s offerings focus on critical care, surgical workflows and infection control, aiming to improve clinical outcomes and operational efficiency. Getinge’s solutions support a range of applications from intensive care and cardiovascular treatments to sterile reprocessing of surgical instruments.
The company’s product portfolio includes sterilization and disinfection equipment, surgical tables and lights, ventilation systems, heart-lung machines and extracorporeal membrane oxygenation (ECMO) devices.
Further Reading
- Five stocks we like better than Getinge
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
- BWX Technologies’ Army Reactor Win Could Redraw Its Nuclear Growth Story
- Meta’s $18 Billion Settlement May Be a Win for Investors
Receive News & Ratings for Getinge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Getinge and related companies with MarketBeat.com's FREE daily email newsletter.
